【摘要】：目的： 研究局部中晚期鼻咽癌IMRT二次掃描在保護(hù)正常組織、提高靶區(qū)劑量及近期療效方面的優(yōu)勢(shì)。 實(shí)驗(yàn)方法： 1.對(duì)比實(shí)驗(yàn)組病例第一次掃描和第二次掃描BODY、GTVnx、 GTVnd、PGTVnx、PGTVnd、PTV1的體積及脊髓距GTVnx、GTVnd的最短距離,腦干距GTVnx的最短距離,以及雙側(cè)晶體距GTVnx的最短距離的改變。并對(duì)比對(duì)照組與實(shí)驗(yàn)組第一次掃描GTVnx、 GTVnd、PGTVnx、PGTVnd、PTV1的體積,了解兩組間靶區(qū)體積有無(wú)差異。實(shí)驗(yàn)組、對(duì)照組靶區(qū)勾畫(huà)均由同一影像科教授和同一腫瘤科教授確認(rèn)。 2.收集實(shí)驗(yàn)組運(yùn)用第二次掃描計(jì)劃繼續(xù)放療后脊髓、腦干、雙側(cè)晶體及PGTVnx、PGTVnd、PTV1的劑量分布,并以PGTVnx224cGy/f、PGTVnd212cGy/f、PTV1185cGy/f作為其相應(yīng)的理論劑量,得出PGTVnx、PGTVnd、PTV1相應(yīng)的V100%、V110%、V95%、V93%的相對(duì)體積數(shù)值。并收集若以第一次掃描方案繼續(xù)放療上述指標(biāo)的數(shù)值。分析前后兩次掃描高危器官及靶區(qū)的劑量分布。 3.對(duì)比實(shí)驗(yàn)組及對(duì)照組病人脊髓、腦干、雙側(cè)晶體及PGTVnx、 PGTVnd、PTV1的平均劑量有無(wú)差異。 4.在放療結(jié)束3-6月后復(fù)查鼻咽及頸部MRI,評(píng)估近期療效。 實(shí)驗(yàn)結(jié)果： 1.用Wilcoxon符號(hào)秩檢驗(yàn)對(duì)比第一、二次掃描BODY、GTVnx、 GTVnd、PGTVnx、PGTVnd、PTV1相應(yīng)的體積、脊髓距GTVnd的最短距離,腦干距GTVnx的最短距離,以及雙側(cè)晶體距GTVnx的最短距離,P0.05,差異有統(tǒng)計(jì)學(xué)意義。脊髓距GTVnx的最短距離及對(duì)照組PGTVnx、PGTVnd、PTV1的體積差異無(wú)統(tǒng)計(jì)學(xué)意義。 2.對(duì)比第二次掃描后放療計(jì)劃脊髓、腦干、左右晶體所受劑量及PGTVnx、PGTVnd、PTV1的平均劑量及按一次性計(jì)劃放療完成的相應(yīng)劑量,除右側(cè)晶體及脊髓外,第二次掃描危及器官的劑量均較第一次掃描低,靶區(qū)劑量均較第一次掃描高,但是僅左側(cè)晶體的劑量差異有統(tǒng)計(jì)學(xué)意義,PGTVnx、PGTVnd、PTV1的V100%、V110%、V95%、V93%兩組對(duì)比中,PGTVnd V100%第二次掃描后計(jì)劃明顯比第一次掃描后計(jì)劃高,P0.05。其余各項(xiàng)兩次掃描后計(jì)劃無(wú)明顯差異。 3.對(duì)比兩組病例脊髓、腦干、左右晶體及PGTVnx、PGTVnd、 PTV1的平均劑量,除左側(cè)晶體及PGTVnx外,實(shí)驗(yàn)組危及器官平均劑量均低于對(duì)照組,靶區(qū)劑量均高于對(duì)照組,其中,實(shí)驗(yàn)組PTV1的劑量較對(duì)照組明顯提高,P0.05。 4.實(shí)驗(yàn)組CR率為41.38%,對(duì)照組CR率為31.03%。CR率提高了11.35%。 實(shí)驗(yàn)結(jié)論： 對(duì)腫瘤體積較大的局部中晚期鼻咽癌,有必要行二次掃描制定放療計(jì)劃使其提高靶區(qū)劑量,保護(hù)危及器官,從而提高患者的CR率。
[Abstract]:Objective: to study the advantages of secondary IMRT scan in protecting normal tissue, increasing target dose and short term curative effect of local advanced nasopharyngeal carcinoma (NPC). Experimental method: 1. The volume of BODY,GTVnx, GTVnd,PGTVnx,PGTVnd,PTV1, the shortest distance from spinal cord to GTVnx,GTVnd, the shortest distance from brainstem to GTVnx, and the shortest distance from bilateral lens to GTVnx were compared. The volume of GTVnx, GTVnd,PGTVnx,PGTVnd,PTV1 was compared between the control group and the experimental group. In the experimental group and the control group, the target area drawing was confirmed by the same imaging professor and the same oncology professor. The dose distributions of spinal cord, brain stem, bilateral lens and PGTVnx,PGTVnd,PTV1 were collected by the second scanning plan, and the relative volume value of V 100 V 110 and V 95 V 93% was obtained by using PGTVnx224cGy/f,PGTVnd212cGy/f,PTV1185cGy/f as its corresponding theoretical dose. The values of the above indexes were collected if the first scan was continued. The dose distribution of high risk organs and target area was analyzed before and after twice scanning. The average dose of spinal cord, brain stem, bilateral lens and PGTVnx, PGTVnd,PTV1 were compared between experimental group and control group. 4. Nasopharyngeal and cervical MRI, were reviewed 3-6 months after radiotherapy to evaluate the short-term efficacy. Experimental results: 1. The relative volume of the first and second scanning BODY,GTVnx, GTVnd,PGTVnx,PGTVnd,PTV1, the shortest distance from the spinal cord to GTVnd, the shortest distance from the brainstem to GTVnx, and the shortest distance from bilateral crystals to GTVnx were compared by Wilcoxon sign rank test (P0.05). There was no significant difference between the shortest distance from spinal cord to GTVnx and the volume of PGTVnx,PGTVnd,PTV1 from control group. 2. The dose of spinal cord, brain stem, left and right lens and the average dose of PGTVnx,PGTVnd,PTV1 and the corresponding dose of radiotherapy according to one time plan were compared after the second scan, except for the right crystal and spinal cord. The dose of the second scan was lower than that of the first scan, and the dose of the target area was higher than that of the first scan. However, there was significant difference in the dose of the left crystal only. In the two groups of PGTVnx,PGTVnd,PTV1 V100 and V11010 and V95 / 93%, the plan of PGTVnd V100% after the second scan was significantly higher than that after the first scan (P0.05). There was no significant difference between the other two scans. 3. The average dose of spinal cord, brain stem, left and right lens and PGTVnx,PGTVnd, PTV1 were compared between the two groups. Except for left lens and PGTVnx, the average dose of endangered organs in the experimental group was lower than that in the control group, and the dose in the target area was higher than that in the control group. The dose of PTV1 in the experimental group was significantly higher than that in the control group (P0.05.4). The CR rate in the experimental group was 41.38, and the 31.03%.CR rate in the control group was increased by 11.35%. Conclusion: it is necessary to make radiotherapy plan for locally advanced nasopharyngeal carcinoma with large tumor volume so as to increase the dose of target area and protect the organ so as to improve the CR rate of patients.
【學(xué)位授予單位】：中南大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2012
【分類(lèi)號(hào)】：R739.63

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張瑜;林志安;潘建基;鄭茁;楊凌;林少俊;鄭飛;;初治鼻咽癌調(diào)強(qiáng)放療與常規(guī)放療的同期對(duì)照研究[J];癌癥;2009年11期

2 羅鳳榮;李雁平;盧功源;徐旭軍;;MRI和CT平掃/增強(qiáng)對(duì)鼻咽癌診斷價(jià)值的比較[J];廣西醫(yī)學(xué);2010年03期

3 賈國(guó)峰;;擺位系統(tǒng)誤差對(duì)鼻咽癌放療劑量分布的影響研究[J];吉林醫(yī)學(xué);2012年06期

4 習(xí)永生;王索宇;李曉泉;;鼻咽癌侵犯相鄰結(jié)構(gòu)的MRI與CT的對(duì)比分析[J];實(shí)用臨床醫(yī)學(xué);2008年11期

5 胡逸民,谷銑之;適形放射治療———腫瘤放射治療新技術(shù)進(jìn)展[J];齊魯腫瘤雜志;1998年04期

6 何俠;朱向幟;翟振宇;沈文榮;魏寶清;;MR/CT和~(18)FDG PET/CT對(duì)鼻咽癌腫瘤區(qū)勾畫(huà)比較研究[J];齊齊哈爾醫(yī)學(xué)院學(xué)報(bào);2007年24期

7 魯世慧;;鼻咽癌常規(guī)放療與適形調(diào)強(qiáng)放療復(fù)發(fā)率及療效比較[J];山東醫(yī)藥;2008年46期

8 付杰;李龍根;傅深;周?chē)?guó)偉;胡超蘇;;鼻咽癌靶區(qū)及關(guān)鍵組織確定CT與MRI比較可行性研究[J];生物醫(yī)學(xué)工程與臨床;2008年06期

9 張瑜;潘建基;陸軍;鄭崴;柏朋剛;陳傳本;潘才住;張秀春;;中晚期鼻咽癌調(diào)強(qiáng)適形放療分段設(shè)計(jì)計(jì)劃的可行性研究[J];實(shí)用癌癥雜志;2006年05期

10 姚剛;王瑞;;鼻咽癌的調(diào)強(qiáng)放射治療探討[J];現(xiàn)代醫(yī)用影像學(xué);2008年03期

，

本文編號(hào)：2265106